Annals of internal medicine · 2006
Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Bommel Eric F H, Hendriksz Tadek R, Huiskes Antonius W L C, Zeegers Antoine G M
Аннотация
BACKGROUND: Anecdotal case reports suggest tamoxifen as a possible treatment for retroperitoneal fibrosis, but a systematic assessment of its effect is not available.
OBJECTIVE: To describe the course and outcomes of patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen.
DESIGN: Prospective, consecutive series.
SETTING: Single tertiary care referral center.
PATIENTS: 19 patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen from April 1998 through April 2005.
INTERVENTION: Tamoxifen, 20 mg orally twice daily.
MEASUREMENTS: Clinical improvement, laboratory variables, and follow-up computed tomography (CT) and gallium scan findings.
RESULTS: Fifteen patients reported substantial resolution of symptoms after a median treatment duration of 2.5 weeks. Erythrocyte sedimentation rate and C-reactive protein also improved. Gallium scanning at follow-up showed incomplete disappearance of pathologic gallium-67 activity. Repeated CT scanning showed slow but steady mass regression in 14 of 15 clinical responders. Five patients failed treatment, including 1 patient who improved clinically. Disease recurred in 1 patient who responded to reintroduction of tamoxifen. One patient developed reversible hepatitis.
LIMITATIONS: This small observational study did not have a control group.
CONCLUSION: Tamoxifen may be a viable therapeutic option in the treatment of retroperitoneal fibrosis.
OBJECTIVE: To describe the course and outcomes of patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen.
DESIGN: Prospective, consecutive series.
SETTING: Single tertiary care referral center.
PATIENTS: 19 patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen from April 1998 through April 2005.
INTERVENTION: Tamoxifen, 20 mg orally twice daily.
MEASUREMENTS: Clinical improvement, laboratory variables, and follow-up computed tomography (CT) and gallium scan findings.
RESULTS: Fifteen patients reported substantial resolution of symptoms after a median treatment duration of 2.5 weeks. Erythrocyte sedimentation rate and C-reactive protein also improved. Gallium scanning at follow-up showed incomplete disappearance of pathologic gallium-67 activity. Repeated CT scanning showed slow but steady mass regression in 14 of 15 clinical responders. Five patients failed treatment, including 1 patient who improved clinically. Disease recurred in 1 patient who responded to reintroduction of tamoxifen. One patient developed reversible hepatitis.
LIMITATIONS: This small observational study did not have a control group.
CONCLUSION: Tamoxifen may be a viable therapeutic option in the treatment of retroperitoneal fibrosis.